{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,7]],"date-time":"2025-11-07T13:21:38Z","timestamp":1762521698565},"reference-count":77,"publisher":"Elsevier BV","issue":"7","license":[{"start":{"date-parts":[[2014,8,1]],"date-time":"2014-08-01T00:00:00Z","timestamp":1406851200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":["elsevier.es","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Gastroenterolog\u00eda y Hepatolog\u00eda"],"published-print":{"date-parts":[[2014,8]]},"DOI":"10.1016\/j.gastrohep.2014.04.004","type":"journal-article","created":{"date-parts":[[2014,6,16]],"date-time":"2014-06-16T23:22:59Z","timestamp":1402960979000},"page":"427-437","update-policy":"http:\/\/dx.doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":2,"title":["Valor de la gen\u00e9tica en la era de la terapia triple frente al virus de la hepatitis C"],"prefix":"10.1016","volume":"37","author":[{"given":"Rosa","family":"Quiles-P\u00e9rez","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Esther Jos\u00e9","family":"Pav\u00f3n-Castillero","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Paloma","family":"Mu\u00f1oz-de-Rueda","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Isabel","family":"Carmona","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Javier","family":"Salmer\u00f3n","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.gastrohep.2014.04.004_bib0005","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1111\/j.1365-2893.2005.00651.x","article-title":"Spontaneous viral clearance following acute hepatitis C infection: A systematic review of longitudinal studies","volume":"13","author":"Micallef","year":"2006","journal-title":"J Viral Hepat"},{"key":"10.1016\/j.gastrohep.2014.04.004_bib0010","doi-asserted-by":"crossref","first-page":"958","DOI":"10.1016\/S0140-6736(01)06102-5","article-title":"Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: A randomised trial","volume":"358","author":"Manns","year":"2001","journal-title":"Lancet"},{"key":"10.1016\/j.gastrohep.2014.04.004_bib0015","doi-asserted-by":"crossref","first-page":"1195","DOI":"10.1056\/NEJMoa1010494","article-title":"Boceprevir for untreated chronic HCV genotype 1 infection","volume":"364","author":"Poordad","year":"2011","journal-title":"N Engl J Med"},{"key":"10.1016\/j.gastrohep.2014.04.004_bib0020","doi-asserted-by":"crossref","first-page":"2405","DOI":"10.1056\/NEJMoa1012912","article-title":"Telaprevir for previously untreated chronic hepatitis C virus infection","volume":"364","author":"Jacobson","year":"2011","journal-title":"N Engl J Med"},{"key":"10.1016\/j.gastrohep.2014.04.004_bib0025","doi-asserted-by":"crossref","first-page":"1105","DOI":"10.1038\/ng.449","article-title":"Genome-wide association of IL28B with response to pegylated interferon-alpha and ribavirin therapy for chronic hepatitis C","volume":"41","author":"Tanaka","year":"2009","journal-title":"Nat Genet"},{"key":"10.1016\/j.gastrohep.2014.04.004_bib0030","doi-asserted-by":"crossref","first-page":"1100","DOI":"10.1038\/ng.447","article-title":"IL28B is associated with response to chronic hepatitis C interferon-alpha and ribavirin therapy","volume":"41","author":"Suppiah","year":"2009","journal-title":"Nat Genet"},{"key":"10.1016\/j.gastrohep.2014.04.004_bib0035","doi-asserted-by":"crossref","first-page":"399","DOI":"10.1038\/nature08309","article-title":"Genetic variation in IL28B predicts hepatitis C treatment-induced viral clearance","volume":"461","author":"Ge","year":"2009","journal-title":"Nature"},{"issue":"1338-45","key":"10.1016\/j.gastrohep.2014.04.004_bib0040","first-page":"1345.e1","article-title":"Genetic variation in IL28B is associated with chronic hepatitis C and treatment failure: A genome-wide association study","volume":"138","author":"Rauch","year":"2010","journal-title":"Gastroenterology"},{"key":"10.1016\/j.gastrohep.2014.04.004_bib0045","doi-asserted-by":"crossref","first-page":"798","DOI":"10.1038\/nature08463","article-title":"Genetic variation in IL28B and spontaneous clearance of hepatitis C virus","volume":"461","author":"Thomas","year":"2009","journal-title":"Nature"},{"key":"10.1016\/j.gastrohep.2014.04.004_bib0050","doi-asserted-by":"crossref","first-page":"1216","DOI":"10.1002\/hep.23850","article-title":"Potential role for interleukin-28B genotype in treatment decision-making in recent hepatitis C virus infection","volume":"52","author":"Grebely","year":"2014","journal-title":"Hepatology"},{"issue":"1586-92","key":"10.1016\/j.gastrohep.2014.04.004_bib0055","article-title":"A polymorphism near IL28B is associated with spontaneous clearance of acute hepatitis C virus and jaundice","volume":"139","author":"Tillmann","year":"2014","journal-title":"Gastroenterology"},{"key":"10.1016\/j.gastrohep.2014.04.004_bib0060","doi-asserted-by":"crossref","first-page":"F23","DOI":"10.1097\/QAD.0b013e3283391d6d","article-title":"Association of a single nucleotide polymorphism near the interleukin-28B gene with response to hepatitis C therapy in HIV\/hepatitis C virus-coinfected patients","volume":"24","author":"Rallon","year":"2014","journal-title":"AIDS"},{"key":"10.1016\/j.gastrohep.2014.04.004_bib0065","doi-asserted-by":"crossref","DOI":"10.1053\/j.gastro.2010.04.013","article-title":"Interleukin-28B polymorphism improves viral kinetics and is the strongest pretreatment predictor of sustained virologic response in genotype 1 hepatitis C virus","volume":"139","author":"Thompson","year":"2010","journal-title":"Gastroenterology"},{"key":"10.1016\/j.gastrohep.2014.04.004_bib0070","doi-asserted-by":"crossref","first-page":"317","DOI":"10.1002\/hep.24074","article-title":"Interleukin-28B polymorphisms are associated with histological recurrence and treatment response following liver transplantation in patients with hepatitis C virus infection","volume":"53","author":"Charlton","year":"2014","journal-title":"Hepatology"},{"issue":"1577-85","key":"10.1016\/j.gastrohep.2014.04.004_bib0075","first-page":"1585.e1","article-title":"Variants in IL28B in liver recipients and donors correlate with response to peg-interferon and ribavirin therapy for recurrent hepatitis C","volume":"139","author":"Fukuhara","year":"2014","journal-title":"Gastroenterology"},{"key":"10.1016\/j.gastrohep.2014.04.004_bib0080","doi-asserted-by":"crossref","first-page":"1518","DOI":"10.1002\/hep.24546","article-title":"Impact of IL28B on treatment outcome in hepatitis C virus G1\/4 patients receiving response-guided therapy with peginterferon alpha-2a (40KD)\/ribavirin","volume":"54","author":"Scherzer","year":"2014","journal-title":"Hepatology"},{"key":"10.1016\/j.gastrohep.2014.04.004_bib0085","doi-asserted-by":"crossref","first-page":"527","DOI":"10.1016\/j.jhep.2011.09.008","article-title":"IL28B polymorphism is associated with treatment response in patients with genotype 4 chronic hepatitis C","volume":"56","author":"Asselah","year":"2014","journal-title":"J Hepatol"},{"key":"10.1016\/j.gastrohep.2014.04.004_bib0090","doi-asserted-by":"crossref","first-page":"336","DOI":"10.1002\/hep.24683","article-title":"Interleukin 28B polymorphism predicts pegylated interferon plus ribavirin treatment outcome in chronic hepatitis C genotype 4","volume":"55","author":"De Nicola","year":"2014","journal-title":"Hepatology"},{"issue":"821-7","key":"10.1016\/j.gastrohep.2014.04.004_bib0095","article-title":"An IL28B polymorphism determines treatment response of hepatitis C virus genotype 2 or 3 patients who do not achieve a rapid virologic response","volume":"139","author":"Mangia","year":"2010","journal-title":"Gastroenterology"},{"key":"10.1016\/j.gastrohep.2014.04.004_bib0100","doi-asserted-by":"crossref","first-page":"1830","DOI":"10.1002\/hep.24298","article-title":"Genetic variation in interleukin 28B with respect to vertical transmission of hepatitis C virus and spontaneous clearance in HCV-infected children","volume":"53","author":"Ruiz-Extremera","year":"2014","journal-title":"Hepatology"},{"key":"10.1016\/j.gastrohep.2014.04.004_bib0105","doi-asserted-by":"crossref","first-page":"e75613","DOI":"10.1371\/journal.pone.0075613","article-title":"Variation of transaminases, HCV-RNA levels and Th1\/Th2 cytokine production during the post-partum period in pregnant women with chronic hepatitis C","volume":"8","author":"Ruiz-Extremera","year":"2014","journal-title":"PLoS One"},{"key":"10.1016\/j.gastrohep.2014.04.004_bib0110","doi-asserted-by":"crossref","first-page":"A1369","DOI":"10.1016\/S0168-8278(11)61371-8","article-title":"Telaprevir substantially improved SVR rates across all IL28B genotypes in the ADVANCE trial","volume":"54","author":"Jacobson","year":"2011","journal-title":"J Hepatol"},{"key":"10.1016\/j.gastrohep.2014.04.004_bib0115","doi-asserted-by":"crossref","first-page":"A13","DOI":"10.1016\/S0168-8278(11)60015-9","article-title":"Similar SVR rates in IL28B CC, CT or TT prior relapser, partial- or null-responder patients treated with telaprevir\/peginterferon\/ribavirin: Retrospective analysis of the REALIZE study","volume":"54","author":"Pol","year":"2011","journal-title":"J Hepatol"},{"key":"10.1016\/j.gastrohep.2014.04.004_bib0120","first-page":"54","article-title":"IL28B polymorphism predicts virologic response in patients with hepatitis C genotype 1 treated with boceprevir (BOC) combination therapy","author":"Poordad","year":"2011","journal-title":"J Hepatol"},{"key":"10.1016\/j.gastrohep.2014.04.004_bib0125","doi-asserted-by":"crossref","first-page":"405","DOI":"10.1038\/nature08825","article-title":"ITPA gene variants protect against anaemia in patients treated for chronic hepatitis C","volume":"464","author":"Fellay","year":"2010","journal-title":"Nature"},{"key":"10.1016\/j.gastrohep.2014.04.004_bib0130","doi-asserted-by":"crossref","first-page":"1323","DOI":"10.1016\/j.jhep.2013.07.014","article-title":"Management of anemia induced by triple therapy in patients with chronic hepatitis C: Challenges, opportunities and recommendations","volume":"59","author":"Romero-Gomez","year":"2013","journal-title":"J Hepatol"},{"key":"10.1016\/j.gastrohep.2014.04.004_bib0135","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1002\/hep.26624","article-title":"Hepatitis C genotype 1 virus with low viral load and rapid virologic response to peginterferon\/ribavirin obviates a protease inhibitor","volume":"59","author":"Pearlman","year":"2014","journal-title":"Hepatology"},{"key":"10.1016\/j.gastrohep.2014.04.004_bib0140","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1189\/jlb.1208761","article-title":"Interferon-lambdas: The modulators of antivirus, antitumor, and immune responses","volume":"86","author":"Li","year":"2009","journal-title":"J Leukoc Biol"},{"key":"10.1016\/j.gastrohep.2014.04.004_bib0145","doi-asserted-by":"crossref","first-page":"135","DOI":"10.2217\/pgs.10.25","article-title":"Pharmacogenetics of hepatitis C therapy","volume":"11","author":"Liapakis","year":"2010","journal-title":"Pharmacogenomics"},{"key":"10.1016\/j.gastrohep.2014.04.004_bib0150","doi-asserted-by":"crossref","first-page":"1246","DOI":"10.1038\/ajg.2011.82","article-title":"Importance of host genetic factors HLA and IL28B as predictors of response to pegylated interferon and ribavirin","volume":"106","author":"De Rueda","year":"2011","journal-title":"Am J Gastroenterol"},{"key":"10.1016\/j.gastrohep.2014.04.004_bib0155","doi-asserted-by":"crossref","first-page":"2307","DOI":"10.1053\/j.gastro.2010.02.009","article-title":"Replicated association between an IL28B gene variant and a sustained response to pegylated interferon and ribavirin","volume":"138","author":"McCarthy","year":"2010","journal-title":"Gastroenterology"},{"key":"10.1016\/j.gastrohep.2014.04.004_bib0160","doi-asserted-by":"crossref","first-page":"980","DOI":"10.1016\/j.jhep.2011.01.050","article-title":"IL28B polymorphisms predict reduction of HCV RNA from the first day of therapy in chronic hepatitis C","volume":"55","author":"Bochud","year":"2011","journal-title":"J Hepatol"},{"key":"10.1016\/j.gastrohep.2014.04.004_bib0165","doi-asserted-by":"crossref","first-page":"1887","DOI":"10.1053\/j.gastro.2006.09.052","article-title":"Interferons alpha and lambda inhibit hepatitis C virus replication with distinct signal transduction and gene regulation kinetics","volume":"131","author":"Marcello","year":"2006","journal-title":"Gastroenterology"},{"key":"10.1016\/j.gastrohep.2014.04.004_bib0170","doi-asserted-by":"crossref","first-page":"1240","DOI":"10.1053\/j.gastro.2010.02.033","article-title":"Interleukin-28b: A key piece of the hepatitis C virus recovery puzzle","volume":"138","author":"Thio","year":"2010","journal-title":"Gastroenterology"},{"key":"10.1016\/j.gastrohep.2014.04.004_bib0175","doi-asserted-by":"crossref","first-page":"903","DOI":"10.1007\/s00535-010-0287-4","article-title":"IL28B in hepatitis C virus infection: Translating pharmacogenomics into clinical practice","volume":"45","author":"Ahlenstiel","year":"2010","journal-title":"J Gastroenterol"},{"key":"10.1016\/j.gastrohep.2014.04.004_bib0180","doi-asserted-by":"crossref","first-page":"1888","DOI":"10.1002\/hep.23912","article-title":"IL28B genotype is associated with differential expression of intrahepatic interferon-stimulated genes in patients with chronic hepatitis C","volume":"52","author":"Urban","year":"2010","journal-title":"Hepatology"},{"key":"10.1016\/j.gastrohep.2014.04.004_bib0185","doi-asserted-by":"crossref","first-page":"499","DOI":"10.1053\/j.gastro.2010.04.049","article-title":"Hepatic ISG expression is associated with genetic variation in interleukin 28B and the outcome of IFN therapy for chronic hepatitis C","volume":"139","author":"Honda","year":"2010","journal-title":"Gastroenterology"},{"key":"10.1016\/j.gastrohep.2014.04.004_bib0190","doi-asserted-by":"crossref","first-page":"608","DOI":"10.1053\/j.gastro.2012.05.011","article-title":"Factors that predict response of patients with hepatitis C virus infection to boceprevir","volume":"143","author":"Poordad","year":"2012","journal-title":"Gastroenterology"},{"key":"10.1016\/j.gastrohep.2014.04.004_bib0195","doi-asserted-by":"crossref","first-page":"1292","DOI":"10.1056\/NEJMoa0908014","article-title":"Telaprevir for previously treated chronic HCV infection","volume":"362","author":"McHutchison","year":"2010","journal-title":"N Engl J Med"},{"key":"10.1016\/j.gastrohep.2014.04.004_bib0200","doi-asserted-by":"crossref","first-page":"S430","DOI":"10.1016\/S0168-8278(12)61106-4","article-title":"100% SVR in IL28B SNP rs12979860C\/C patients treated with 12 weeks of telaprevir, peginterferon and ribavirin in the PROVE2 trial.","volume":"56","author":"Bronowicki","year":"2012","journal-title":"Journal of Hepatology"},{"key":"10.1016\/j.gastrohep.2014.04.004_bib0205","unstructured":"Nelson P, Feld, Fried, Jacobson, Pockros, Sulkowski, Zeuzem, Bengtsson, George, Friedman, on behalf of the CONCISE Study Team. High SVR Rates (SVR4) for 12-Week Total Telaprevir Combination Therapy in IL28B CC Treatment-Na\u00efves and Prior Relapsers With G1 Chronic Hepatitis C: CONCISE Interim Analysis. Presented at the 48th Annual Meeting of the European Association for the Study of the Liver: EASL International Liver Congress, Amsterdam, The Netherlands, April 24-28, 2013. Journal of Hepatology 2013."},{"key":"10.1016\/j.gastrohep.2014.04.004_bib0210","series-title":"Presented at the 48th Annual Meeting of the European Association for the Study of the Liver (The International Liver CongressTM 2013)","article-title":"Efficacy of Telaprevir Dosed Twice Daily versus Every 8 Hours by IL28B Genotype: Results from the Phase III OPTIMIZE Study","author":"Buti M","year":"2013"},{"key":"10.1016\/j.gastrohep.2014.04.004_bib0215","doi-asserted-by":"crossref","first-page":"2417","DOI":"10.1056\/NEJMoa1013086","article-title":"Telaprevir for retreatment of HCV infection","volume":"364","author":"Zeuzem","year":"2011","journal-title":"N Engl J Med"},{"key":"10.1016\/j.gastrohep.2014.04.004_bib0220","doi-asserted-by":"crossref","first-page":"392","DOI":"10.1016\/j.jhep.2013.11.003","article-title":"EASL Clinical Practice Guidelines: Management of hepatitis C virus infection","volume":"60","author":"European Association for the Study of the Live","year":"2014","journal-title":"Journal of Hepatology"},{"key":"10.1016\/j.gastrohep.2014.04.004_bib0225","doi-asserted-by":"crossref","first-page":"1014","DOI":"10.1056\/NEJMoa1014463","article-title":"Response-guided telaprevir combination treatment for hepatitis C virus infection","volume":"365","author":"Sherman","year":"2011","journal-title":"N Engl J Med"},{"key":"10.1016\/j.gastrohep.2014.04.004_bib0230","doi-asserted-by":"crossref","first-page":"1371","DOI":"10.1007\/s10620-012-2484-x","article-title":"Estimates of HCV-1 patients attaining RVR following dual therapy with peg-interferon and ribavirin","volume":"58","author":"Andriulli","year":"2013","journal-title":"Dig Dis Sci"},{"key":"10.1016\/j.gastrohep.2014.04.004_bib0235","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1016\/j.jhep.2009.10.003","article-title":"Shortened treatment duration in treatment-naive genotype 1 HCV patients with rapid virological response: A meta-analysis","volume":"52","author":"Moreno","year":"2010","journal-title":"J Hepatol"},{"key":"10.1016\/j.gastrohep.2014.04.004_bib0240","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1016\/j.jhep.2013.07.040","article-title":"Identification of na\u00efve HCV-1 patients with chronic hepatitis who may benefit from dual therapy with peg-interferon and ribavirin","volume":"60","author":"Andriulli","year":"2014","journal-title":"J Hepatol"},{"key":"10.1016\/j.gastrohep.2014.04.004_bib0245","doi-asserted-by":"crossref","first-page":"5879","DOI":"10.3748\/wjg.v18.i41.5879","article-title":"Several factors including ITPA polymorphism influence ribavirin-induced anemia in chronic hepatitis C","volume":"18","author":"Tsubota","year":"2012","journal-title":"World J Gastroenterol"},{"key":"10.1016\/j.gastrohep.2014.04.004_bib0250","doi-asserted-by":"crossref","first-page":"997","DOI":"10.1053\/he.2000.5789","article-title":"Hemolytic anemia induced by ribavirin therapy in patients with chronic hepatitis C virus infection: Role of membrane oxidative damage","volume":"31","author":"De Franceschi","year":"2000","journal-title":"Hepatology"},{"key":"10.1016\/j.gastrohep.2014.04.004_bib0255","doi-asserted-by":"crossref","first-page":"389","DOI":"10.1002\/hep.24068","article-title":"Inosine triphosphatase genetic variants are protective against anemia during antiviral therapy for HCV2\/3 but do not decrease dose reductions of RBV or increase SVR","volume":"53","author":"Thompson","year":"2011","journal-title":"Hepatology"},{"key":"10.1016\/j.gastrohep.2014.04.004_bib0260","doi-asserted-by":"crossref","first-page":"245","DOI":"10.1016\/j.jhep.2011.02.023","article-title":"Clinical Practice Guidelines: Management of hepatitis C virus infection","volume":"55","author":"European Association for the Study of the Live","year":"2011","journal-title":"J Hepatol"},{"key":"10.1016\/j.gastrohep.2014.04.004_bib0265","doi-asserted-by":"crossref","DOI":"10.1053\/j.gastro.2013.07.051","article-title":"Effects of ribavirin dose reduction vs erythropoietin for boceprevir-related anemia in patients with chronic hepatitis C virus genotype 1 infection--a randomized trial","volume":"145","author":"Poordad","year":"2013","journal-title":"Gastroenterology"},{"key":"10.1016\/j.gastrohep.2014.04.004_bib0270","doi-asserted-by":"crossref","first-page":"858","DOI":"10.1111\/jvh.12113","article-title":"Inosine triphosphatase deficiency helps predict anaemia, anaemia management and response in chronic hepatitis C therapy","volume":"20","author":"Clark","year":"2013","journal-title":"J Viral Hepat"},{"key":"10.1016\/j.gastrohep.2014.04.004_bib0275","doi-asserted-by":"crossref","first-page":"124","DOI":"10.1016\/j.cgh.2006.10.008","article-title":"Impact of ribavirin dose reductions in hepatitis C virus genotype 1 patients completing peginterferon alfa-2a\/ribavirin treatment","volume":"5","author":"Reddy","year":"2007","journal-title":"Clin Gastroenterol Hepatol"},{"key":"10.1016\/j.gastrohep.2014.04.004_bib0280","doi-asserted-by":"crossref","first-page":"1061","DOI":"10.1053\/gast.2002.35950","article-title":"Adherence to combination therapy enhances sustained response in genotype-1-infected patients with chronic hepatitis C","volume":"123","author":"McHutchison","year":"2002","journal-title":"Gastroenterology"},{"key":"10.1016\/j.gastrohep.2014.04.004_bib0285","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1053\/j.gastro.2006.11.011","article-title":"Impact of reducing peginterferon alfa-2a and ribavirin dose during retreatment in patients with chronic hepatitis C","volume":"132","author":"Shiffman","year":"2007","journal-title":"Gastroenterology"},{"key":"10.1016\/j.gastrohep.2014.04.004_bib0290","doi-asserted-by":"crossref","first-page":"1981","DOI":"10.1111\/j.1572-0241.2008.01957.x","article-title":"Early predictors of anemia in patients with hepatitis C genotype 1 treated with peginterferon alfa-2a (40KD) plus ribavirin","volume":"103","author":"Reau","year":"2008","journal-title":"Am J Gastroenterol"},{"key":"10.1016\/j.gastrohep.2014.04.004_bib0295","doi-asserted-by":"crossref","first-page":"243","DOI":"10.1111\/j.1365-2893.2004.00490.x","article-title":"Changes in haemoglobin during interferon alpha-2b plus ribavirin combination therapy for chronic hepatitis C virus infection","volume":"11","author":"Sulkowski","year":"2004","journal-title":"J Viral Hepat"},{"key":"10.1016\/j.gastrohep.2014.04.004_bib0300","doi-asserted-by":"crossref","first-page":"964","DOI":"10.1016\/j.jhep.2013.06.030","article-title":"Effect of gender and ITPA polymorphisms on ribavirin-induced anemia in chronic hepatitis C patients","volume":"59","author":"Scherzer","year":"2013","journal-title":"J Hepatol"},{"key":"10.1016\/j.gastrohep.2014.04.004_bib0305","doi-asserted-by":"crossref","first-page":"470","DOI":"10.1111\/jvh.12047","article-title":"Role of IL28B and inosine triphosphatase polymorphisms in the treatment of chronic hepatitis C virus genotype 6 infection","volume":"20","author":"Seto","year":"2013","journal-title":"J Viral Hepat"},{"key":"10.1016\/j.gastrohep.2014.04.004_bib0310","doi-asserted-by":"crossref","first-page":"415","DOI":"10.1002\/hep.24058","article-title":"Influence of ITPA polymorphisms on decreases of hemoglobin during treatment with pegylated interferon, ribavirin, and telaprevir","volume":"53","author":"Suzuki","year":"2011","journal-title":"Hepatology"},{"key":"10.1016\/j.gastrohep.2014.04.004_bib0315","doi-asserted-by":"crossref","first-page":"84","DOI":"10.1093\/infdis\/jir210","article-title":"IL28B but not ITPA polymorphism is predictive of response to pegylated interferon, ribavirin, and telaprevir triple therapy in patients with genotype 1 hepatitis C","volume":"204","author":"Chayama","year":"2011","journal-title":"J Infect Dis"},{"key":"10.1016\/j.gastrohep.2014.04.004_bib0320","doi-asserted-by":"crossref","first-page":"667","DOI":"10.1016\/j.jhep.2013.05.017","article-title":"Clinical milestones for the prediction of severe anemia by chronic hepatitis C patients receiving telaprevir-based triple therapy","volume":"59","author":"Ogawa","year":"2013","journal-title":"J Hepatol"},{"key":"10.1016\/j.gastrohep.2014.04.004_bib0325","article-title":"Effectiveness and safety of reduced-dose telaprevir-based triple therapy in chronic hepatitis C patients","author":"Sezaki","year":"2013","journal-title":"Hepatol Res"},{"key":"10.1016\/j.gastrohep.2014.04.004_bib0330","doi-asserted-by":"crossref","first-page":"1437","DOI":"10.1053\/j.gastro.2005.01.059","article-title":"Hepatic gene expression discriminates responders and nonresponders in treatment of chronic hepatitis C viral infection","volume":"128","author":"Chen","year":"2005","journal-title":"Gastroenterology"},{"key":"10.1016\/j.gastrohep.2014.04.004_bib0335","doi-asserted-by":"crossref","first-page":"1021","DOI":"10.1053\/j.gastro.2010.11.039","article-title":"Interferon-induced gene expression is a stronger predictor of treatment response than IL28B genotype in patients with hepatitis C","volume":"140","author":"Dill","year":"2014","journal-title":"Gastroenterology"},{"key":"10.1016\/j.gastrohep.2014.04.004_bib0340","doi-asserted-by":"crossref","first-page":"712","DOI":"10.1038\/clpt.2011.189","article-title":"Genetic variants of interferon-stimulated genes and IL-28B as host prognostic factors of response to combination treatment for chronic hepatitis C","volume":"90","author":"Lopez-Rodriguez","year":"2011","journal-title":"Clin Pharmacol Ther"},{"key":"10.1016\/j.gastrohep.2014.04.004_bib0345","doi-asserted-by":"crossref","first-page":"164","DOI":"10.1038\/ng.2521","article-title":"A variant upstream of IFNL3 (IL28B) creating a new interferon gene IFNL4 is associated with impaired clearance of hepatitis C virus","volume":"45","author":"Prokunina-Olsson","year":"2014","journal-title":"Nat Genet"},{"key":"10.1016\/j.gastrohep.2014.04.004_bib0350","doi-asserted-by":"crossref","first-page":"1109","DOI":"10.1084\/jem.20130012","article-title":"IL28B expression depends on a novel TT\/-G polymorphism which improves HCV clearance prediction","volume":"210","author":"Bibert","year":"2014","journal-title":"J Exp Med"},{"key":"10.1016\/j.gastrohep.2014.04.004_bib0355","doi-asserted-by":"crossref","first-page":"322","DOI":"10.1111\/apt.12568","article-title":"The novel ss469415590 variant predicts virological response to therapy in patients with chronic hepatitis C virus type 1 infection","volume":"39","author":"Covolo","year":"2014","journal-title":"Aliment Pharmacol Ther"},{"key":"10.1016\/j.gastrohep.2014.04.004_bib0360","doi-asserted-by":"crossref","DOI":"10.1097\/QAD.0000000000000052","article-title":"IFNL4 ss469415590 variant is a better predictor than ILF3 (IL28B) rs12979860 of pegylated interferon-alpha\/ribavirin therapy failure in hepatitis C virus\/HIV-1 coinfected patients","author":"Franco","year":"2014","journal-title":"AIDS"},{"key":"10.1016\/j.gastrohep.2014.04.004_bib0365","doi-asserted-by":"crossref","first-page":"2817","DOI":"10.1097\/01.aids.0000433234.78807.54","article-title":"Variation in IFNL4 genotype and response to interferon-based therapy of hepatitis C in HIV-positive patients with acute and chronic hepatitis C","volume":"27","author":"Kramer","year":"2014","journal-title":"AIDS"},{"key":"10.1016\/j.gastrohep.2014.04.004_bib0370","doi-asserted-by":"crossref","DOI":"10.1007\/s00535-013-0924-9","article-title":"Predictive value of the IFNL4 polymorphism on outcome of telaprevir, peginterferon, and ribavirin therapy for older patients with genotype 1b chronic hepatitis C","author":"Fujino","year":"2014","journal-title":"J Gastroenterol"},{"key":"10.1016\/j.gastrohep.2014.04.004_bib0375","doi-asserted-by":"crossref","first-page":"S463","DOI":"10.1016\/S0168-8278(10)61193-2","article-title":"Slc28a2 65c>T predict sustained virological response in patients with Hepatitis C treated with interferon and ribavirin, considering all HCV genotype and genotype 1\/4","volume":"52","author":"D\u2019Avolio","year":"2010","journal-title":"J Hepatol"},{"key":"10.1016\/j.gastrohep.2014.04.004_bib0380","doi-asserted-by":"crossref","first-page":"669","DOI":"10.1016\/j.jhep.2012.11.027","article-title":"Impact of genetic SLC28 transporter and ITPA variants on ribavirin serum level, hemoglobin drop and therapeutic response in patients with HCV infection","volume":"58","author":"Rau","year":"2014","journal-title":"J Hepatol"},{"key":"10.1016\/j.gastrohep.2014.04.004_bib0385","doi-asserted-by":"crossref","first-page":"826","DOI":"10.1111\/j.1478-3231.2011.02727.x","article-title":"Contribution of ribavirin transporter gene polymorphism to treatment response in peginterferon plus ribavirin therapy for HCV genotype 1b patients","volume":"32","author":"Tsubota","year":"2014","journal-title":"Liver Int"}],"container-title":["Gastroenterolog\u00eda y Hepatolog\u00eda"],"original-title":[],"language":"es","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0210570514001411?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0210570514001411?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2018,10,3]],"date-time":"2018-10-03T09:55:17Z","timestamp":1538560517000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0210570514001411"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2014,8]]},"references-count":77,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2014,8]]}},"alternative-id":["S0210570514001411"],"URL":"https:\/\/doi.org\/10.1016\/j.gastrohep.2014.04.004","relation":{},"ISSN":["0210-5705"],"issn-type":[{"value":"0210-5705","type":"print"}],"subject":[],"published":{"date-parts":[[2014,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Valor de la gen\u00e9tica en la era de la terapia triple frente al virus de la hepatitis C","name":"articletitle","label":"Article Title"},{"value":"Gastroenterolog\u00eda y Hepatolog\u00eda","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.gastrohep.2014.04.004","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2014 Elsevier Espa\u00f1a, S.L. and AEEH y AEG. All rights reserved.","name":"copyright","label":"Copyright"}]}}